Top 5 Net Payout Yield Companies To Watch For 2014

NEW YORK (TheStreet) -- The world is so awash in liquidity that big banks may soon feel forced to charge some of their customers for taking deposits.

The excess liquidity might be news to consumers who find themselves highly "illiquid" in tough economic times, but the Federal Reserve's "highly accommodative stance of monetary policy" has consequences, especially for savers.

As the economy has gone through its ups and downs, depositors over the past several decades have seen radical changes in how banks work to gather deposits, or turn them away. Depending on how old you are, you might remember banks giving away toasters and other goodies to new depositors. My sister and I received nifty little transistor radios when our parents opened savings passbook accounts for each of us during the 1970s.

Top 5 Insurance Stocks To Buy For 2015: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer's disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors' Opinion:

• [By Keith Speights]

  Easy as A-B-C?
  While the initial drop stemmed from first-quarter results, some of the fall in Amgen stock is due to additional factors. Other big biotechs dropped during part of the same time frame from general market pressures. Take a look at the "ABCs" of big biotech -- Amgen, Biogen Idec (NASDAQ: BIIB  ) , and Celgene (NASDAQ: CELG  ) .

• [By Ben Levisohn]

  The S&P 500 gained 0.3% to 1,843.80 today as Boston Scientific (BSX), Dow Chemical (DOW) and Biogen Idec (BIIB) rose. The Dow Jones Industrial Average slid 0.3% to 16,414.44.

• [By Maxx Chatsko]

  Rising biotech stars Celgene (NASDAQ: CELG  ) , Biogen Idec (NASDAQ: BIIB  ) , and Gilead Sciences (NASDAQ: GILD  ) have all crushed the market in the last year. Heck, even Amgen has been rewarded by the market for making biologics and biosimilars a top priority. Shares of each company have shot upwards on earnings acceleration expectations thanks to promising late stage pipelines. Multiple potential megablockbusters in the wings could bring in billions in sales by the end of the decade if approved and launched successfully.

Top 5 Net Payout Yield Companies To Watch For 2014: PowerShares Dynamic Large Cap Growth Portfolio (PWB)

PowerShares Dynamic Large Cap Growth Portfolio (the Fund) seeks investment results that correspond generally to the price and yield of an equity index called the Dynamic Large Cap Growth Intellidex Index (the Intellidex). The Fund will normally invest at least 80% of its assets in common stocks of large-cap companies. A company is considered to be a large-cap company if it falls within the Intellidex model. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Intellidex. The Intellidex consists of 50 United States large-cap growth stocks selected principally on the basis of their capital appreciation potential as identified by the AMEX (the Intellidex Provider) pursuant to its Intellidex methodology.

The Fund, using an indexing investment approach, attempts to replicate the performance of the Intellidex. The Fund generally will invest in all of the stocks comprising the Intellidex in proportion to their weightings in the Intellidex. The Fund�� investment advisor is PowerShares Capital Management LLC.

Advisors' Opinion:

• [By Paul Ausick]

  Two ETFs to watch are Guggenheim Solar (NYSEMKT: TAN), which is up more than 80% so far this year, and PowerShares WilderHill Clean Energy (NYSEMKT: PWB), up more than 40%. Both are less liquid than the company shares and their gains have been smaller, but both should do well if the solar stocks keep running up.

Top 5 Net Payout Yield Companies To Watch For 2014: Gentium SpA(GENT)

Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. It develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also offers sulglicotide that is developed from swine duodenum, and has ulcer healing and gastrointestinal protective properties in South Korea; and urokinase, which is made from human urine to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.

Advisors' Opinion:

• [By Sean Williams]

  A parabolic problem
  It has also been a year to remember for shareholders of biopharmaceutical company Gentium (NASDAQ: GENT  ) whose share price has catapulted approximately 600% off its lows thanks to growth in its lead drug Defibrotide (known as Defitelio in the European Union).

• [By James Oberweis]

  Gentium Spa (GENT) is focused on the development and commercialization of its leading product, defibrotide, to treat certain complications arising from chemotherapy, and bone marrow and stem cell transplantation therapy.

• [By Jake L'Ecuyer]

  Shares of Jazz Pharmaceuticals Public Limited Company (NASDAQ: JAZZ) got a boost, shooting up 7.77 percent to $123.65 after the company announced its plans to buy Gentium SpA (NASDAQ: GENT) for around $1 billion.

Top 5 Net Payout Yield Companies To Watch For 2014: Givaudan SA (GIVN)

Givaudan SA is a Switzerland-based holding company engaged in the fragrance and flavor industry. The Company has two business divisions: Fragrances and Flavors. The Fragrances business segment comprises the manufacture and sale of fragrances into three global business units: Fine Fragrances, comprising signature fragrances and line extensions, Consumer Products, comprising fabric and personal care, hair and skin care, household and air care, as well as oral care, and Fragrance Ingredients. The Flavors business division comprises the manufacture and sale of flavors into four business units: Beverages, comprising flavors for soft drinks, fruit juices and instant beverages; Dairy, comprising ice cream, yoghurt, desserts and yellow fats; Savory, covering soups and sauces, among others; and Confectionery. The Company is also engaged in research and development activities, which comprises the development of a palette of perfumery raw materials, both synthetic and natural. Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Given Imaging (Nasdaq: GIVN  ) , whose recent revenue and earnings are plotted below.